Key points from article :
Precision medicine company Human Longevity has secured a significant funding boost of $39.8 million to accelerate its mission of extending human health and lifespan. This funding will fuel the development of its AI-driven health risk and recommendation platform, expand its global reach, and introduce innovative technologies and services.
Founded by genomics pioneer J. Craig Venter, HLI leverages advanced technologies to identify and address potential health issues early. By analyzing vast amounts of health data, the company aims to shift healthcare from a reactive to a proactive approach, focusing on prevention and personalized interventions.
With the new funding, HLI plans to expand its network of health assessment centers beyond its current locations in the US. New sites are slated for Europe, Asia, Saudi Arabia, and other GCC countries, bringing HLI's innovative approach to a wider global audience.
A key component of HLI's offerings is the 100+ Longevity Care program. This comprehensive program utilizes a combination of whole genome sequencing, advanced imaging, and other health assessments to detect early signs of age-related diseases. By identifying potential health risks, HLI can provide targeted interventions to increase both healthspan and lifespan.
HLI's research has also yielded significant results, including a study that demonstrated the effectiveness of integrating whole-genome sequencing, metabolomics, and advanced imaging in identifying and mitigating major health risks.
The Series B round, which exceeded its initial target, was led by TVM Capital Healthcare and included participation from both new and existing investors. This infusion of capital will enable HLI to continue pushing the boundaries of longevity medicine and make a significant impact on global health.
